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What’s already known about this topic? 
Daylight PDT is an effective, almost painless field-treatment for actinic keratosis. 
The PpIX-weighted light dose a patient receives during treatment is an important determinant of effective 
treatment. 
Most centres undertaking daylight PDT do not objectively measure light exposure doses during treatment, 
and there is a lack of confidence in understanding the exposure conditions required. 
What does this study add? 
A new method for estimating a patient’s PpIX-weighted exposure dose from a single illuminance 
measurement. 
Detailed objective information from nine locations across the UK and Ireland with respect to possible 
treatment conditions for daylight PDT. 
Increased understanding and confidence in the exposure conditions for effective daylight PDT in the UK. 
Abstract 
Background: Daylight PDT (dPDT) is an effective and nearly painless treatment for field-change actinic 
keratosis. Measuring the protoprophyrin-IX (PpIX)-weighted exposure dose can give an indication of when 
conditions are most viable for effective dPDT. It would be advantageous for practitioners if more detailed 
information of exposure dose and appropriate treatment conditions were available. Where sophisticated 
measurement equipment is unavailable, simpler and more cost-effective methods of dose measurement are 
desirable. 
Objectives: To devise a model whereby illuminance data can be converted into PpIX-weighted exposure 
dose, and to use this model to estimate appropriate times for dPDT across the UK and Ireland. 
Methods: Spectral irradiance data were analysed to obtain a conversion model for illuminance to PpIX-
weighted dose. This model was applied to historic illuminance data from nine sites to obtain PpIX-weighted 
dose across the UK and Ireland. Temperature data and an analysis of conservatory-based dPDT were also 
considered. 
Results: A distribution of the expected PpIX-weighted dose across the nine locations is presented; however, 
the temperature data showed that it could be too cold for dPDT even when there is sufficient light exposure. 
Conservatory-based dPDT could extend the times in the year for possible treatment. 
Conclusions: This proposed conversion model provides a means of using an illuminance reading to 
calculate the PpIX-weighted exposure dose. Dosimetry of dPDT may be carried out simply and at low cost 
using the presented method, however the results presented may be used as a guide for those considering 
dPDT, without the need to conduct measurements themselves. 
 
Introduction 
Photodynamic therapy (PDT) is an attractive treatment for superficial non-melanoma skin cancers and 
dysplasia, including actinic keratosis (AK).  Conventional PDT (cPDT) can be performed over a relatively 
large surface area (up to approximately 5x10 cm2)1, with a high efficacy, good cosmetic outcome and high 
patient satisfaction2–5. In cPDT, light is delivered to the target area, typically using a bank of red light 
emitting diodes (LEDs)1. The dose of light delivered to the skin surface is the product of the irradiance at 
the skin surface and the exposure time, and sufficient photobleaching of the photosensitiser, 
protoprophyrin-IX (PpIX), is required for effective treatment. Both irradiance and time are easily controlled 
in cPDT, which allows for accurate determination of the delivered light dose. However a disadvantage of 
this treatment is that it can be painful6–8 and requires multiple visits to hospitals for patients with extensive 
field-change, requiring large area treatment. 
A less painful and more efficient alternative to cPDT for the treatment of AK is daylight photodynamic 
therapy (dPDT), wherein the sun is used as the light source for treatment6,9,10. The sun is a broadband 
source containing ultraviolet, visible and infrared electromagnetic radiation which targets all of the 
absorption peaks of PpIX. Daylight PDT treatment times are longer than those for cPDT, with an 
international consensus recommending at least two hours of daylight exposure for effective treatment11. 
This exposure time can be controlled, however the irradiance of daylight at the treatment site is somewhat 
harder to predict, particularly in locations with variable weather conditions such as the United Kingdom. 
This makes accurate dosimetry of dPDT more challenging in contrast to cPDT, and is a limiting factor for 
physicians and patients as there is a degree of uncertainty and thus lack of confidence in treatment. 
Previous studies have measured the light dose during dPDT with differing methodologies including: the 
use of a specialised device worn on the wrist to measure directly the PpIX-weighted light dose10; 
spectroradiometers to measure daylight spectral irradiance12; and handheld light meters9. These techniques 
require expensive and often bespoke equipment with associated support from a metrology specialist such 
as a medical physicist, while one of the advantages of dPDT itself is that it is a relatively simple treatment 
that does not require high specialist input. If the dosimetry associated with dPDT could be simplified so 
that it is cheap and simple to perform, the treatment may be more attractive where practitioners want the 
reassurance of accurate dosimetry but don’t have the specialist support to perform some of the previously 
mentioned techniques. This would be particularly important in countries such as the UK, where weather 
conditions and light levels can vary dramatically during a day. 
As a solution, we propose that illuminance, as measured in lux, can be used in a simple calculation to 
determine the effective PpIX-weighted irradiance, and subsequently the PpIX-weighted exposure dose. To 
validate this model, we compared the modelling results to direct spectral irradiance measurements made at 
three sites across the UK. Following validation, historical illuminance and temperature data from nine sites 
across the UK were analysed, and could then be used to recommend appropriate times of the year and days 
for performing dPDT. This could facilitate more informed clinical practice, and provide information for 
centres considering dPDT as a treatment option. 
 
Materials and Methods 
Conversion Model 
Data collection 
Over six thousand spectral irradiance measurements of daylight were obtained from Public Health 
England’s (PHE) monitoring station in Chilton, UK (51.575 °N, 1.318 °W), in 15 minute intervals between 
the hours of 09:00 and 17:00, from March to October 2015. The measurements were made in the horizontal 
plane using a Glacier X TE-cooled CCD array spectroradiometer (BWTek Inc, 19 SheaWay, Newark, USA), 
coupled to D7-SMA diffuser (Bentham Instruments Ltd, Reading, UK) by optical fibre. The instrument 
was calibrated in an environmentally controlled laboratory using 1000 W tungsten-halogen lamps, calibrated 
for spectral irradiance to the Physikalisch-Technische Bundesanstalt (PTB, Braunschweig und Berlin, 
https://www.ptb.de/) traceable reference standards. Full day data were excluded if there were missing time 
points during the day and time points were excluded if they occurred after sunset. 
 
Model 
The illuminance and the PpIX-weighted irradiance were obtained from the product of the spectral 
irradiance data and the luminosity13 and the PpIX absorption14 function respectively. A ratio of PpIX-
weighted irradiance to illuminance for each data point was determined and an iterative process was 
undertaken to produce a model which accurately converted illuminance to PpIX-weighted irradiance. At 
each stage in the iterative process, results from the current model were compared to the values of PpIX-
weighted irradiance derived from the measurements. 
 
Model Verification 
To test the developed model, daylight spectral irradiance data (acquired similarly to the Chilton monitoring 
station) from three UK sites – Salisbury (51.07 °N, 1.79 °W), Nottingham (53.07 °N, 1.24 °W) and Dundee 
(54.46 °N, 2.97 °W), were obtained; the model was applied to the data and the percentage difference in 
actual and calculated PpIX-weighted irradiances calculated. This was used as a metric to evaluate the 
conversion model in different locations. 
 
Statistical Analysis 
Statistical analysis was performed in JMP software, using bivariate analysis or ANOVA where appropriate. 
Significance is set at p<0.01. 
 
UK Location analysis 
Public Health England operates a solar monitoring network15 at nine locations in the UK and Ireland (Fig. 
1); illuminance is recorded using Macam Photometrics SD-104 Lcos detectors. Over half a million 
measurement data points were obtained at 5 minute intervals between 09:00 and 17:00 from 1st January to 
31st December in 2013-15 inclusive. A custom-written MATLAB program, using the model previously 
described, was used to convert the illuminance values to PpIX-weighted irradiance and subsequently PpIX-
weighted exposure dose. In addition, temperature data (data accessed from Weather Underground)16 for 
each location were obtained over the same period as the illuminance data. 
The mean daily maximal temperature and effective dose data were used to recommend months and times 
of the day for each location when daylight PDT could be performed. When setting the minimum criteria 
required for effective daylight PDT, a temperature of 10 °C and a dose of 4 J cm-2 were used based upon 
recent published literature12,17,18. A treatment time of two hours was assumed. 
The predicted months and times of day were also calculated for conservatory dPDT, assuming no 
dependence on outside temperature and a reduction in the PpIX exposure dose by 25% 19. 
 Results 
Model 
Figure 2 shows the PpIX-weighted-irradiance-to-illuminance ratio as a function of the illuminance.  Lower 
illuminance values are associated with higher ratios. As a first iteration, a logarithmic equation (Equation 1) 
is fitted to the data (R2=0.34). 
 Ratio  0.903194 0.03533  vLn E     (1) 
where Ev is the illuminance. 
The calculated PpIX-weighted irradiance (Equation 1 multiplied by the illuminance) has a mean difference 
of 0.53% (SD = 7.85%) when compared to the true PpIX-weighted irradiance. There is, however, a 
dependence of the percentage error on time of day (p<0.01) and year (p<0.01) with Equation 1 
undercompensating around solar noon, and overcompensating at the start and end of the day. 
The elevation angle of the sun (position of the sun in the sky) and the declination angle of the Earth (tilt of 
the Earth relative to the sun) (data provided by NOAA ESRL Global Monitoring Division, Boulder, 
Colorado, USA)20 are used to correct for these trends (Equation 2):  
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where Ee is the PpIX-weighted irradiance and Ev, Φe, Φe(max) and Φd are the illuminance, solar elevation 
angle, maximum solar elevation angle in the year, and the declination angle respectively. 
Using Equation 2 the mean percentage difference between the calculated and the actual values is 0.04% 
(SD=6.80%) and the percentage error is independent of time of day or time of year. 
 
Model verification 
The model has been verified resulting in a good agreement against spectral irradiance data from Salisbury, 
Nottingham and Dundee. Figure 3 shows the percentage difference between the calculated PpIX-weighted 
irradiance and the true PpIX-weighted irradiance at three locations. The mean differences are 1.76% 
(SD=8.01%), -4.13% (SD=3.95%) and 2.19% (SD=4.88%) against the Nottingham, Salisbury and Dundee 
data respectively. 
 
UK Location Analysis 
Using the developed model, historic illuminance data from nine sites around the UK were analysed in order 
to present the expected mean PpIX-weighted exposure doses in each location throughout the year.  Figure 
4 displays the mean dose for each month over the three-year period 2013 – 2015 at each location. The mean 
daily maximal temperatures for each location are shown in Figure 5. 
Analysis of the most appropriate treatment times of the day, following the aforementioned criteria (PpIX 
dose > 4 J cm-2 and ambient temperature > 10 °C), is given in Table 1 with full data displayed in Figure 6. 
Table 2 details when treatment would be possible in a conservatory - the temperature restriction of 10 °C 
has been removed and the dose data has been reduced by 25% to take account of the attenuation by glass19. 
 
Discussion 
Daylight PDT is increasingly used and has a strong evidence-base to support its application in Europe and 
Australia6,21. However, the use of dPDT has somewhat lagged behind in the UK, although several centres 
commenced this treatment modality within the last year. There is understandable concern about the use of 
a treatment in the UK that relies on the weather, and guidance and confidence in the use of effective light 
delivery is required. 
The model presented here can be used to accurately calculate the PpIX-weighted exposure dose during 
dPDT using only the measured illuminance, and the time and date, duration and location of treatment to 
provide confidence to presubscribers of dPDT. The model first takes the illuminance reading and converts 
this reading in to PpIX-weighted irradiance - this is done by first accounting for the logarithmic trend of 
the conversion factor shown in Figure 2, and secondly by correcting for the elevation angle, which is specific 
to the location of measurement, and the declination angle, which is specific to the time of measurement. 
This process produces a corrected, accurate PpIX-weighted irradiance value, which can then be multiplied 
by the time of exposure to output the PpIX-weighted exposure dose. 
Illuminance can be measured using inexpensive lux-meters, which makes this an attractive option in clinics 
where more advanced dosimetry techniques are not available. The developed model shows good accuracy 
in different locations (Fig. 3), which adds further confidence to the robustness of the model. This method 
accounts for different weather conditions, which are factored in to the error margins presented. 
Deciding on the suitable months to use dPDT in different geographical locations primarily depends on the 
minimum PpIX-weighted exposure dose for effective treatment. There is a general consensus among 
several published studies which state that above a certain value there is no significant increase in treatment 
efficacy, ergo, there exists a minimum dose for effective treatment. However, there is no firm consensus 
on what this minimum dose is for effective AK treatment, with values ranging from 3-16 J cm-2 9,12,17,18,22,23. 
One study10 even found no correlation between effective dose and treatment efficacy for a range of 0.2-28 
J cm-2. Varying reports on minimum light doses for dPDT can potentially be explained by the different 
measurement systems used in these studies, and the different characteristics of patients and AK lesions 
treated. Thinner AK lesions respond better to dPDT than thicker lesions, although there is no evidence yet 
to suggest that higher doses of light exposure equate to improved treatment efficacy for any grade of 
lesion17. 
The difference in efficacies seen between different thicknesses of AK lesions is perhaps due to the depth 
of penetration of the incident daylight. The peak PpIX absorption during dPDT is in the blue region of the 
electromagnetic spectrum where penetration depth into the skin is relatively low compared to the red 
portion of the spectrum where there is less absorption by PpIX, but much increased tissue penetration24. 
Therefore, it may be important to account for the nature of the lesion treated before assessing a minimum 
dose required. The 2012 study by Wiegell et al.17 indicated that combining analysis of all AK thicknesses 
could give a minimum dose whereby above a certain threshold there is no significant change in efficacy 
with further increasing light dose, whereas separating analysis of AK thicknesses gave no significant effects 
of light dose on efficacy between the individual grades of lesion. Therefore, we analysed our data against a 
minimum PpIX-weighted light dose of 4 J cm-2 based on current best estimates from the literature, and 
while this dose is lower than the recommendations from the European Consensus guidelines11, it is based 
upon more extensive and up-to-date data from recent publications12,17,18.  
Using this value, the mean (+SD) PpIX-weighted dose each month for each location is shown in Figure 4. 
From these data, Table 1 was constructed showing the possible times of the year for treatment. It is worth 
noting that as these data encompass all weather conditions, it is likely that on clear days the expected dose 
would be towards or even above the one standard deviation presented in Figure 4. 
Another important consideration is the ambient temperature. It is generally considered that it would not be 
comfortable for patients to remain outdoors in temperatures <10 °C 11. For this reason, temperature data 
were included in this analysis. Data presented in Table 1 and Figure 6 show that suitable months for dPDT 
begin in March (London), April (Inverness, Glasgow, Malin Head, Belfast, Leeds, Swansea, Camborne) or 
May (Lerwick), and finish in October (Lerwick, Inverness, Glasgow and Belfast), November (Malin Head 
and Belfast) or December (Swansea, London and Camborne). We established that even though there may 
be a sufficiently high light dose in some months, the ambient temperature may be too low, becoming a 
limiting factor in recommending dPDT, in particular for the early months of the year. One must also 
consider weather conditions such as wind, where even though the ambient temperature may be above 10 
°C, it may feel too cold or uncomfortable for patients to remain outdoors for extended periods of time. 
Therefore, even with guidelines, recommendation of dPDT should remain at the discretion of the clinician 
and patient. 
The use of conservatories could facilitate dPDT when temperature or other weather conditions would 
otherwise hinder treatment if there is still enough daylight. To achieve an equivalent exposure dose to 
dPDT, the treatment time for conservatory-based dPDT should be increased by 33% to account for the 
attenuation of visible light through window glass. This would mean that, based on a recommended 
treatment time of two hours for dPDT, conservatory-based dPDT treatment time should be recommended 
at two hours and forty minutes to maintain dose equivalence between the two methods. Studies suggest 
that low irradiance PDT with longer treatment times can still be as effective as conventional PDT19,25,26. A 
randomised, multicentre study found no statistical significance when comparing lesion response rate and 
adverse effects between patients who had dPDT for 1.5 and 2.5 hour exposures10. This indicates that 
extending the time of exposure by forty minutes for conservatory-based dPDT with a lower irradiance to 
maintain dose equivalence with dPDT should have little to no effect on lesion response rate or treatment 
tolerability. 
Table 2 gave the recommended months for conservatory dPDT. These data showed that conservatory 
based dPDT can be recommended earlier in the year, in January (Belfast, Leeds, Swansea, London and 
Camborne) or February (Lerwick, Inverness, Glasgow and Malin Head), while at the end of the year the 
months for viable treatment conclude in October (Lerwick and Glasgow), November (Inverness, Malin 
Head, Belfast and Leeds) and December (Swansea, London and Camborne). These data suggest that, for 
south of the UK in particular, conservatory-based dPDT could be carried out for nearly the whole calendar 
year – in contrast to standard dPDT - owing to the higher temperatures and reduced wind effects inside 
the conservatory. The times in the day suitable for conservatory-based dPDT in the summer months will 
likely extend beyond the minimum time ranges presented in Table 2. 
Tables 1 and 2 also give the time required to achieve the minimum PpIX exposure dose in the months with 
the highest mean dose. These data suggest that the minimum light dose can be reached in as little as 16.1 
minutes in the southerly locations. It is important to note that these presented times do not serve as a 
recommendation for treatment times, as there are currently no studies that suggest treatment times as low 
as these can provide effective dPDT. In fact, it is suggested that treatment times less than one hour may 
provide insufficient time for photosensitiser production27. However, these data can give confidence to 
practitioners of dPDT that interruptions in the patients’ daylight exposure (e.g. patchy cloud cover or rain) 
may be tolerable provided the recommended treatment protocol is followed. 
The analysis of the most appropriate times of the day for dPDT showed suitability in the start and end 
months from 09:00 to either 16:00 or 17:00. Select time intervals in the ‘unsuitable’ months may also be 
appropriate for dPDT, e.g. around solar noon on clear days when there is the most daylight, even though 
the mean monthly dose itself is deemed too low for effective treatment. Again, temperatures and weather 
effects in these periods could limit treatment. Conservatory-based dPDT slightly narrows time ranges for 
achieving minimum PpIX-weighted dose due to the reduction in daylight. 
 
Conclusions 
The presented data provide confidence that daylight PDT can be performed throughout the UK, from the 
most southerly to the most northerly locations, and that effective exposure doses can be achieved. Indeed, 
dPDT can be performed at times of the year in the UK not previously considered, particularly when a 
conservatory is used to combat the low ambient temperatures. Illuminance measurements are simple to 
perform and the equipment required is not expensive. The model for estimating the expected PpIX-
weighted exposure dose for dPDT in the UK has been developed based on spectral irradiance 
measurements, and verified against spectral irradiance data from other UK locations with good agreement. 
It is anticipated that this model could help inform those involved in delivering dPDT clinical services, when 
combined with an inexpensive personal lux-meter, about patient-specific dose delivery during dPDT. Those 
considering dPDT may look to these results as a guide and to provide confidence without the need for 
conducting measurements themselves, or alternatively may carry out dosimetry using this presented method 
of determining PpIX-weighted exposure dose from a single measurement of illuminance. 
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Table 1 
  
Start End Shortest time to achieve 
minimum dose 
 
Latitude (°N) Month Time Month Time Month Time 
(minutes) 
Lerwick 60.15 May 09:00 – 16:00 Oct 09:00 – 16:00 May 22.9 
Inverness 57.48 Apr 09:00 – 16:00 Oct 09:00 – 16:00 Jul 21.4 
Glasgow 55.85 Apr 09:00 – 16:00 Oct 09:00 – 16:00 Jul 21.3 
Malin Head 55.35 Apr 09:00 – 16:00 Nov 09:00 – 16:00 Jun 20.4 
Belfast 54.60 Apr 09:00 – 17:00 Nov 09:00 – 17:00 Jun 19.6 
Leeds 53.80 Apr 09:00 – 16:00 Oct 09:00 – 16:00 Jul 19.6 
Swansea 51.62 Apr 09:00 – 17:00 Dec 09:00 – 17:00 Jun 16.1 
London 51.51 Mar 09:00 – 17:00 Dec 09:00 – 17:00 Jul 18.3 
Camborne 50.21 Apr 09:00 – 17:00 Dec 09:00 – 17:00 Jun 16.2 
 
Table 1: Start and end treatment months and times of the day for dPDT at each location, with respect to 
minimum conditions for dPDT – PpIX-weighted exposure dose >4 J cm-2 and ambient temperature >10 
°C. These recommendations are based on a 2-hour exposure time. For the times of day presented, these 
represent the times in which treatment should take place, e.g. for Lerwick in May, treatment should not 
start earlier than 09:00 and finish no later than 16:00. Shortest times to reach the minimum PpIX 
exposure dose in the months with the highest mean dose are included, i.e. on average, how long will it 
take to receive the minimum PpIX exposure dose in the corresponding month. These minimum times are 
indiscriminate of weather conditions. 
  
Table 2 
Conservatory-
based dPDT 
 
Start End Shortest time to achieve 
minimum dose 
  Latitude (°N) Month Time Month Time Month Time 
(minutes) 
Lerwick 60.15 Feb 09:00 – 16:00 Oct 09:00 – 16:00 May 30.5 
Inverness 57.48 Feb 09:00 – 16:00 Nov 10:00 – 15:00 Jul 28.5 
Glasgow 55.85 Feb 09:00 – 16:00 Oct 09:00 – 16:00 Jul 28.4 
Malin Head 55.35 Feb 09:00 – 16:00 Nov 10:00 – 15:00 Jun 27.1 
Belfast 54.60 Jan 10:00 – 15:00 Nov 09:00 – 15:00 Jun 26.1 
Leeds 53.80 Jan 10:00 – 15:00 Nov 09:00 – 15:00 Jul 26.1 
Swansea 51.62 Jan 09:00 – 15:00 Dec 10:00 – 15:00 Jun 21.4 
London 51.51 Jan 09:00 – 15:00 Dec 09:00 – 15:00 Jul 24.3 
Camborne 50.21 Jan 09:00 – 16:00 Dec 10:00 – 15:00 Jun 21.6 
 
Table 2: Start and end treatment months and times of the day for conservatory-based dPDT at each 
location, accounting for a 25% attenuation of daylight, and negating any temperature effects. These 
recommendations are based on a 2.5-hour exposure time. For the times of day presented, these represent 
the times in which treatment should take place, e.g. for Lerwick in February, treatment should not start 
earlier than 09:00 and finish no later than 16:00. Shortest times to reach the minimum PpIX exposure 
dose in the months with the highest mean dose are included, i.e. on average, how long will it take to 
receive the minimum PpIX exposure dose in the corresponding month. These minimum times are 
indiscriminate of weather conditions. 
